Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

PURPOSE: CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase 4 and 6 inhibitors in ABC. METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Javier Salvador, Jacot, William, Dent, Susan, Martin, Miguel, Ring, Alistair, Cottu, Paul, Lu, Janice, Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Menon-Singh, Lakshmi, Zamagni, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505291/
https://www.ncbi.nlm.nih.gov/pubmed/34414532
http://dx.doi.org/10.1007/s10549-021-06334-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505291/
https://www.ncbi.nlm.nih.gov/pubmed/34414532
http://dx.doi.org/10.1007/s10549-021-06334-0

Ejemplares similares